Table 2 Unadjusted and adjusted linear regression analyses with flow-mediated vasodilation (ΔFMD) as the dependent variable
Unadjusted analyses | Adjusted analysesa | ||||
|---|---|---|---|---|---|
β (95 % CI) | p value | β (95 % CI) | p value | ||
Age | −0.07 (−0.14, 0.01) | 0.09 | – | ||
Gender | 0.38 (−0.89, 1.66) | 0.55 | – | ||
bDMARDs | −1.07 (−2.31, 0.18) | 0.09 | – | ||
CRP | Baseline | −0.01 (−0.18, 0.16) | 0.92 | −0.02 (−0.18, 0.15) | 0.86 |
Change | 0.04 (−0.01, 0.09) | 0.13 | 0.05 (−0.01, 0.10) | 0.08 | |
ESR | Baseline | −0.01 (−0.07, 0.05) | 0.83 | 0.01 (−0.06, 0.08) | 0.76 |
Change | 0.04 (−0.02, 0.09) | 0.18 | 0.04 (−0.01, 0.09) | 0.15 | |
DAS28 | Baseline | 0.24 (−0.82, 1.29) | 0.66 | 0.29 (−0.73, 1.31) | 0.57 |
Change | 0.02 (−1.23, 1.27) | 0.98 | −0.25 (−1.43, 0.93) | 0.67 | |
ASDAS | Baseline | −0.01 (−0.40, 0.38) | 0.96 | 0.08 (−0.53, 0.68) | 0.78 |
Change | 0.14 (−0.31, 0.58) | 0.52 | 0.14 (−0.52, 0.81) | 0.63 | |
LDL-c | Baseline | 0.01 (0.62, 0.63) | 0.98 | −0.13 (−0.75, 0.50) | 0.69 |
Change | −0.17 (−0.91, 0.57) | 0.65 | −0.06 (−0.80, 0.68) | 0.87 | |
HDL-c | Baseline | −0.54 (−1.78, 0.70) | 0.39 | −0.26 (−1.70, 1.17) | 0.72 |
Change | −1.33 (−3.18, 0.52) | 0.16 | −1.43 (−3.28, 0.42) | 0.13 | |
AIx, change | −0.09 (−0.18, 0.01) | 0.06 | −0.09 (−0.18, 0.00) | < 0.05 | |
aPWV, change | −0.07 (−0.58, 0.43) | 0.78 | −0.14 (−0.66, 0.38) | 0.59 | |
CP height, change | −3.51 (−5.28, −1.73) | < 0.001 | −3.10 (−4.95, −1.25) | 0.001 | |
c-IMT, change | 3.55 (−4.51, 11.62) | 0.38 | 3.96 (−4.77, 12.70) | 0.37 | |
Rosuvastatin dose | 0.02 (−0.03, 0.07) | 0.48 | 0.01 (−0.04, 0.06) | 0.76 | |